Logo image of BON

BON NATURAL LIFE LTD-A (BON) Stock Fundamental Analysis

NASDAQ:BON - Nasdaq - KYG144921213 - Common Stock - Currency: USD

1.23  -0.02 (-1.6%)

After market: 1.25 +0.02 (+1.63%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BON. BON was compared to 85 industry peers in the Chemicals industry. While BON seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, BON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year BON was profitable.
In the past year BON has reported a negative cash flow from operations.
In the past 5 years BON has always been profitable.
The reported operating cash flow has been mixed in the past 5 years: BON reported negative operating cash flow in multiple years.
BON Yearly Net Income VS EBIT VS OCF VS FCFBON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

1.2 Ratios

BON has a Return On Assets (0.64%) which is comparable to the rest of the industry.
BON has a Return On Equity of 0.91%. This is comparable to the rest of the industry: BON outperforms 45.88% of its industry peers.
BON has a worse Return On Invested Capital (2.44%) than 67.06% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BON is in line with the industry average of 6.84%.
The 3 year average ROIC (8.52%) for BON is well above the current ROIC(2.44%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.64%
ROE 0.91%
ROIC 2.44%
ROA(3y)9.09%
ROA(5y)10.38%
ROE(3y)11.65%
ROE(5y)16.28%
ROIC(3y)8.52%
ROIC(5y)10.57%
BON Yearly ROA, ROE, ROICBON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

BON has a Profit Margin of 1.67%. This is comparable to the rest of the industry: BON outperforms 52.94% of its industry peers.
BON's Profit Margin has declined in the last couple of years.
BON has a Operating Margin (7.86%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of BON has declined.
Looking at the Gross Margin, with a value of 29.82%, BON is in line with its industry, outperforming 56.47% of the companies in the same industry.
BON's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 7.86%
PM (TTM) 1.67%
GM 29.82%
OM growth 3Y-28.15%
OM growth 5Y-16.51%
PM growth 3Y-54.74%
PM growth 5Y-36.12%
GM growth 3Y2.25%
GM growth 5Y-1.53%
BON Yearly Profit, Operating, Gross MarginsBON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 10 20 30

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BON is creating value.
BON has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BON has more shares outstanding
Compared to 1 year ago, BON has a worse debt to assets ratio.
BON Yearly Shares OutstandingBON Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K
BON Yearly Total Debt VS Total AssetsBON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 1.43, we must say that BON is in the distress zone and has some risk of bankruptcy.
BON has a worse Altman-Z score (1.43) than 67.06% of its industry peers.
A Debt/Equity ratio of 0.15 indicates that BON is not too dependend on debt financing.
BON has a Debt to Equity ratio of 0.15. This is amongst the best in the industry. BON outperforms 83.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 1.43
ROIC/WACC0.6
WACC4.09%
BON Yearly LT Debt VS Equity VS FCFBON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M

2.3 Liquidity

A Current Ratio of 2.42 indicates that BON has no problem at all paying its short term obligations.
BON's Current ratio of 2.42 is fine compared to the rest of the industry. BON outperforms 64.71% of its industry peers.
BON has a Quick Ratio of 2.32. This indicates that BON is financially healthy and has no problem in meeting its short term obligations.
BON's Quick ratio of 2.32 is amongst the best of the industry. BON outperforms 84.71% of its industry peers.
Industry RankSector Rank
Current Ratio 2.42
Quick Ratio 2.32
BON Yearly Current Assets VS Current LiabilitesBON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

4

3. Growth

3.1 Past

BON shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -97.84%.
BON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.75% yearly.
The Revenue for BON has decreased by -19.23% in the past year. This is quite bad
The Revenue has been growing slightly by 7.78% on average over the past years.
EPS 1Y (TTM)-97.84%
EPS 3Y-71.08%
EPS 5Y-44.75%
EPS Q2Q%-95.59%
Revenue 1Y (TTM)-19.23%
Revenue growth 3Y-2.21%
Revenue growth 5Y7.78%
Sales Q2Q%-11.13%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue is expected to grow by 24.08% on average over the next years. This is a very strong growth
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year77.63%
Revenue Next 2Y45.28%
Revenue Next 3Y34.64%
Revenue Next 5Y24.08%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BON Yearly Revenue VS EstimatesBON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 20M 40M 60M 80M 100M
BON Yearly EPS VS EstimatesBON Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 50 100 150

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.46, the valuation of BON can be described as very cheap.
Based on the Price/Earnings ratio, BON is valued cheaply inside the industry as 98.82% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.21, BON is valued rather cheaply.
Industry RankSector Rank
PE 0.46
Fwd PE N/A
BON Price Earnings VS Forward Price EarningsBON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BON is valued cheaply inside the industry as 98.82% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.52
BON Per share dataBON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 200

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

BON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BON NATURAL LIFE LTD-A

NASDAQ:BON (7/1/2025, 8:00:00 PM)

After market: 1.25 +0.02 (+1.63%)

1.23

-0.02 (-1.6%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)N/A N/A
Earnings (Next)09-22 2025-09-22
Inst Owners1.59%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap209.10K
Analysts0
Price TargetN/A
Short Float %N/A
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.46
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B 0
P/tB 0
EV/EBITDA 0.52
EPS(TTM)2.7
EY219.51%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-45.47
FCFYN/A
OCF(TTM)-45.43
OCFYN/A
SpS140.26
BVpS258.27
TBVpS253.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.64%
ROE 0.91%
ROCE 4.13%
ROIC 2.44%
ROICexc 2.44%
ROICexgc 2.48%
OM 7.86%
PM (TTM) 1.67%
GM 29.82%
FCFM N/A
ROA(3y)9.09%
ROA(5y)10.38%
ROE(3y)11.65%
ROE(5y)16.28%
ROIC(3y)8.52%
ROIC(5y)10.57%
ROICexc(3y)8.65%
ROICexc(5y)11.01%
ROICexgc(3y)8.8%
ROICexgc(5y)11.18%
ROCE(3y)13.84%
ROCE(5y)17.18%
ROICexcg growth 3Y-44.37%
ROICexcg growth 5Y-33.89%
ROICexc growth 3Y-44.35%
ROICexc growth 5Y-33.92%
OM growth 3Y-28.15%
OM growth 5Y-16.51%
PM growth 3Y-54.74%
PM growth 5Y-36.12%
GM growth 3Y2.25%
GM growth 5Y-1.53%
F-Score2
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA 2.24
Cap/Depr 0.64%
Cap/Sales 0.03%
Interest Coverage 6.18
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.42
Quick Ratio 2.32
Altman-Z 1.43
F-Score2
WACC4.09%
ROIC/WACC0.6
Cap/Depr(3y)764.29%
Cap/Depr(5y)1250.29%
Cap/Sales(3y)6.63%
Cap/Sales(5y)12.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.84%
EPS 3Y-71.08%
EPS 5Y-44.75%
EPS Q2Q%-95.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-19.23%
Revenue growth 3Y-2.21%
Revenue growth 5Y7.78%
Sales Q2Q%-11.13%
Revenue Next Year77.63%
Revenue Next 2Y45.28%
Revenue Next 3Y34.64%
Revenue Next 5Y24.08%
EBIT growth 1Y-68.34%
EBIT growth 3Y-29.74%
EBIT growth 5Y-10.01%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-319.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1084.66%
OCF growth 3YN/A
OCF growth 5YN/A